このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

ThermoGenesis Holdings マネジメント

マネジメント基準チェック /44

現在、CEO に関する十分な情報がありません。

主要情報

Chris Xu

最高経営責任者

US$520.0k

報酬総額

CEO給与比率	100.0%
CEO在任期間	7.6yrs
CEOの所有権	n/a
経営陣の平均在職期間	7.3yrs
取締役会の平均在任期間	7.4yrs

経営陣の近況

Recent updates

It's Down 52% But ThermoGenesis Holdings, Inc. (NASDAQ:THMO) Could Be Riskier Than It Looks

Apr 17

Does ThermoGenesis Holdings' (NASDAQ:THMO) CEO Salary Compare Well With Industry Peers?

Dec 15

ThermoGenesis EPS misses by $0.27, misses on revenue

Nov 12

CEO報酬分析

ThermoGenesis Holdings の収益と比較して、Chris Xu の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Mar 31 2024	n/a	n/a	-US$15m
Dec 31 2023	US$520k	US$520k	-US$18m
Sep 30 2023	n/a	n/a	-US$14m
Jun 30 2023	n/a	n/a	-US$14m
Mar 31 2023	n/a	n/a	-US$14m
Dec 31 2022	US$699k	US$519k	-US$11m
Sep 30 2022	n/a	n/a	-US$10m
Jun 30 2022	n/a	n/a	-US$9m
Mar 31 2022	n/a	n/a	-US$11m
Dec 31 2021	US$748k	US$500k	-US$11m
Sep 30 2021	n/a	n/a	-US$12m
Jun 30 2021	n/a	n/a	-US$12m
Mar 31 2021	n/a	n/a	-US$14m
Dec 31 2020	US$2m	US$505k	-US$16m
Sep 30 2020	n/a	n/a	-US$18m
Jun 30 2020	n/a	n/a	-US$17m
Mar 31 2020	n/a	n/a	-US$12m
Dec 31 2019	US$472k	US$472k	-US$9m
Sep 30 2019	n/a	n/a	-US$13m
Jun 30 2019	n/a	n/a	-US$13m
Mar 31 2019	n/a	n/a	-US$39m
Dec 31 2018	US$653k	US$460k	-US$40m
Sep 30 2018	n/a	n/a	-US$32m
Jun 30 2018	n/a	n/a	-US$32m
Mar 31 2018	n/a	n/a	-US$6m
Dec 31 2017	US$1m	US$216k	-US$6m

報酬と市場: Chrisの総報酬 ($USD 520.00K ) は、 US市場 ($USD 667.11K ) の同様の規模の企業の平均とほぼ同じです。

報酬と収益: Chrisの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Chris Xu (53 yo)

7.6yrs

在職期間

US$520,000

報酬

Dr. Xiaochun Xu, also known as Chris, M.B.A. Ph D., serves as Chief Executive Officer and Chairman at ImmuneCyte Life Sciences, Inc. Dr. Xu is the Founder, Chairman and Chief Executive Officer of Boyalife...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Xiaochun Xu	Chairman of the Board & CEO	7.6yrs	US$520.00k	データなし
Jeffery Cauble	CFO & Corporate Secretary	7.3yrs	US$264.00k	0.00025% $ 6.2
Haihong Zhu	Chief Operating Officer	6.4yrs	US$460.00k	0% $ 0

7.3yrs

平均在職期間

53yo

平均年齢

経験豊富な経営陣: THMOの経営陣は経験豊富で経験豊富です（平均在職期間は7.3年）。

取締役

名称	ポジション	在職期間	報酬	所有権
Xiaochun Xu	Chairman of the Board & CEO	8.3yrs	US$520.00k	データなし
Russell Medford	Independent Director	7.3yrs	US$54.50k	0% $ 0
Solomon Hamburg	Member of Clinical & Scientific Advisory Board	10.1yrs	データなし	データなし
Lars Norgren	Member of Clinical Advisory Board	8.3yrs	データなし	データなし
James Xu	Independent Director	less than a year	US$13.38k	データなし
Joseph Thomis	Independent Director	7.4yrs	US$56.00k	0% $ 0
Biao Xi	Independent Director	less than a year	US$10.00k	データなし

7.4yrs

平均在職期間

58yo

平均年齢

経験豊富なボード: THMOの取締役会は経験豊富であると考えられます ( 7.4年の平均在任期間)。

ThermoGenesis Holdings マネジメント

マネジメント 基準チェック /44

主要情報

経営陣の近況

ThermoGenesis Holdings, Inc., Annual General Meeting, Dec 14, 2023

Less than half of directors are independent

ThermoGenesis Holdings, Inc., Annual General Meeting, Dec 15, 2022

Less than half of directors are independent

ThermoGenesis Holdings, Inc. Announces Board Changes

ThermoGenesis Holdings, Inc. Board Changes

Recent updates

ThermoGenesis Holdings Receives Notice from Nasdaq Due to Non-Compliance with Minimum of $2.5 Million in Stockholders’ Equity for Continued Listing Under Nasdaq’s Listing Rule 5550(b)(1)

ThermoGenesis Holdings, Inc. announced delayed 10-Q filing

ThermoGenesis Holdings Receives Notice from Nasdaq Regarding Non-Compliance with Nasdaq’s Listing Rule 5550(b)(1)

ThermoGenesis Holdings, Inc. announced delayed annual 10-K filing

New major risk - Share price stability

ThermoGenesis Holdings Receives Letter from The Nasdaq Stock Market Regarding Non-Compliance with the Minimum Bid Price Requirement for Continued Listing on the Nasdaq Capital Market

ThermoGenesis Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $1.288 million.

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

New minor risk - Share price stability

ThermoGenesis Holdings, Inc. to Report Q3, 2023 Results on Nov 13, 2023

ThermoGenesis Holdings, Inc., Annual General Meeting, Dec 14, 2023

Consensus revenue estimates fall by 25%

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

ThermoGenesis Holdings, Inc. to Report Q2, 2023 Results on Aug 10, 2023

First quarter 2023 earnings: EPS and revenues miss analyst expectations

ThermoGenesis Holdings, Inc. to Report Q1, 2023 Results on May 15, 2023

It's Down 52% But ThermoGenesis Holdings, Inc. (NASDAQ:THMO) Could Be Riskier Than It Looks

Forecast breakeven date moved forward to 2023

Full year 2022 earnings: EPS and revenues miss analyst expectations

ThermoGenesis Regains Compliance with Nasdaq Minimum Bid Price Requirement

Price target decreased to US$1.00

Less than half of directors are independent

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

ThermoGenesis Holdings, Inc. to Report Q1, 2023 Results on Nov 10, 2022

ThermoGenesis Holdings, Inc., Annual General Meeting, Dec 15, 2022

ThermoGenesis Holdings, Inc. has completed a Composite Units Offering in the amount of $2.0547 million.

Nasdaq Grants Extension to ThermoGenesis Holdings to Regain Compliance

Forecast breakeven date pushed back to 2024

Less than half of directors are independent

ThermoGenesis reports Q2 results

ThermoGenesis Holdings, Inc. to Report Q4, 2022 Results on Aug 11, 2022

ThermoGenesis Holdings, Inc. Announces Board Changes

ThermoGenesis Holdings, Inc. Board Changes

ThermoGenesis Holdings, Inc. to Report Q1, 2022 Results on May 19, 2022

ThermoGenesis Holdings, Inc. announced delayed 10-Q filing

Forecast to breakeven in 2022

Price target decreased to US$6.00

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Third quarter 2021 earnings released: US$0.15 loss per share (vs US$0.37 loss in 3Q 2020)

Is ThermoGenesis Holdings (NASDAQ:THMO) Using Too Much Debt?

Thermogenesis Awards Nih Sbir Phase I Grant to Develop Key Cell Processing Disposable for Quintessence Automated Manufacturing of Gene-Engineered Autologous Cell (Geac) Therapies

Consensus forecasts updated

Second quarter 2021 earnings released: US$0.38 loss per share (vs US$1.02 loss in 2Q 2020)

Is ThermoGenesis Holdings (NASDAQ:THMO) A Risky Investment?

Consensus revenue estimates fall to US$9.94m

First quarter 2021 earnings released: US$0.21 loss per share (vs US$1.11 loss in 1Q 2020)

When Will ThermoGenesis Holdings, Inc. (NASDAQ:THMO) Become Profitable?

Consensus revenue estimates fall to US$13.6m

Full year 2020 earnings released: US$2.60 loss per share (vs US$3.36 loss in FY 2019)

ThermoGenesis Holdings, Inc. to Report Q4, 2020 Results on Mar 17, 2021

Here's Why ThermoGenesis Holdings (NASDAQ:THMO) Can Afford Some Debt

New 90-day high: US$3.85

Thermogenesis Holdings, Inc. Launches A Gmp Compliant Automated Cell Washing and Reformulation System -- Pxp™-Lavare -- for Car-T Manufacturing

New 90-day high: US$2.73

New 90-day low: US$2.10

Does ThermoGenesis Holdings' (NASDAQ:THMO) CEO Salary Compare Well With Industry Peers?

Earnings beat expectations, revenue disappoints

Third quarter 2020 earnings released: US$0.37 loss per share

ThermoGenesis EPS misses by $0.27, misses on revenue

ThermoGenesis Holdings, Inc. to Report Q3, 2020 Results on Nov 12, 2020

New 90-day low: US$2.55

New 90-day low: US$3.24

New 90-day low - US$3.66

First half earnings released

ThermoGenesis Holdings, Inc. to Report Q2, 2020 Results on Aug 12, 2020

CEO報酬分析

CEO（最高経営責任者

在職期間

報酬

マネジメント基準チェック /44